Macroeconomic Operating Context and Transmission Channels

The operational performance of the domestic pharmaceutical manufacturing sector during 2026-Q2 must be evaluated against persistent macroeconomic imbalances and structural adjustments within Bangladesh. Real economic expansion has moderated, with GDP growth recorded at 4.14% per annum for FY2023 according to World Bank WDI data, alongside a provisional estimate of 6.0% for FY23 by the Bangladesh Bureau of Statistics (BBS). Industrial activity operates under considerable inflationary pressure. CPI inflation reached an annual average of 10.47% according to World Bank 2024 metrics, corroborated by BBS data showing headline inflation at 9.7% in Dec 2024. These elevated price levels continue to suppress real domestic purchasing power and restrict discretionary household expenditure, directly impacting the demand profile for retail pharmaceutical formulations.

`` +-------------------------------------------------------------------------+ | MACROECONOMIC BASELINE INDICATORS | +---------------------------------------------------+---------------------+ | Indicator | Value / Magnitude | +---------------------------------------------------+---------------------+ | Real GDP Growth (World Bank WDI FY2023) | 4.14% per annum | | Real GDP Growth (BBS provisional FY23) | 6.0% | | CPI Inflation (World Bank 2024 annual average) | 10.47% | | CPI Inflation (BBS Dec 2024) | 9.7% | | Foreign Exchange Reserves (IMF BPM6, Dec 2024) | $31.07 billion | | Exchange Rate (Bangladesh Bank mid-rate end-Dec) | 122.75 BDT per USD | | Fiscal Deficit share of GDP (Revised FY2023-24) | 4.7% | | Public Debt share of GDP (World Bank / IMF 2024) | 40.1% | | Merchandise Exports (Adjusted FY2023-24) | $44.5 billion | | Merchandise Imports (Goods, c.i.f., FY2023-24) | $63.7 billion | | Remittance Inflows (FY2023-24) | $23.91 billion | | Non-Performing Loan Ratio (Late 2025 Basel III) | 35.73% | +---------------------------------------------------+---------------------+ ``

External sector constraints compound these domestic demand pressures. Foreign exchange reserves evaluated under the IMF BPM6 methodology stood at $31.07 billion as of Dec 2024, according to Bangladesh Bank. Concurrently, the official mid-rate exchange rate depreciated to 122.75 BDT per USD at end-Dec 2024. This currency realignment has elevated the local currency cost of imported equipment, packaging materials, and active compounds. While external stability has derived support from remittance inflows of $23.91 billion (reflecting a 10.66% year-on-year increase in FY2023-24), total merchandise imports of $63.7 billion substantially exceeded merchandise exports of $44.5 billion in FY2023-24.

Fiscal and financial sector indicators further define the policy operating boundary. The fiscal deficit stood at 4.7% of GDP under the Ministry of Finance revised budget for FY2023-24, while public debt reached 40.1% of GDP according to World Bank and IMF 2024 data. In the domestic banking system, balance sheet stress escalated sharply following the Bangladesh Bank Basel III reclassification in late 2025, which established a non-performing loan ratio of 35.73%. This systemic impairment of the financial sector severely impedes bank intermediation, restricts private credit creation, and elevates working capital financing frictions for capital-intensive pharmaceutical manufacturers.

Structural Concentration and Market Bifurcation

The manufacturing architecture of the pharmaceutical sector displays extreme industrial concentration. Officially, Bangladesh currently has 258 pharmaceutical manufacturers. This enterprise base successfully supplies 98% of domestic finished formulations, demonstrating an advanced domestic capability in final formulation and commercial distribution.

`` +-------------------------------------------------------------------------+ | INDUSTRIAL STRUCTURE & CONCENTRATION | +---------------------------------------------------+---------------------+ | Structural Parameter | Measurement | +---------------------------------------------------+---------------------+ | Total Licensed Manufacturers | 258 enterprises | | Market Share of Dominant Cohort (20 companies) | Approximately 94% | | Market Share of Residual Base (238 companies) | 6% of output | | Domestic Finished Formulation Self-Sufficiency | 98% | | International Export Destinations | 166 markets | +---------------------------------------------------+---------------------+ ``

Aggregate market participation is characterized by structural bifurcation. Production is heavily consolidated: 20 companies account for approximately 94% of total domestic production. This leaves the remaining 238 companies to share just 6% of output.

This asymmetry generates distinct operating realities across the industry. The 20 dominant producers command substantial economies of scale, modern automated plants, established marketing networks, and regulatory compliance units capable of navigating overseas licensing procedures. Conversely, the long tail of 238 manufacturers survives on minimal market share. These smaller producers contend with sub-scale operations, limited liquidity, and an inability to absorb rising input expenses. As a result, the capacity to invest in facility upgrades, research, and regulatory documentation is concentrated within a narrow group of market leaders.

Domestic Margin Compression and Financial Performance

Recent operational data reflects severe revenue stress across the domestic market, penetrating the primary manufacturing tier. According to data from IQVIA, 64 of the country's top 100 pharmaceutical manufacturers recorded negative growth in 2025. Conversely, only 32 of the top 100 pharmaceutical companies recorded positive revenue growth.

`` +-------------------------------------------------------------------------+ | DOMESTIC GROWTH TRAJECTORY (TOP 100 PRODUCERS) | +---------------------------------------------------+---------------------+ | Performance Classification (IQVIA 2025 Data) | Number of Firms | +---------------------------------------------------+---------------------+ | Enterprises Recording Negative Revenue Growth | 64 companies | | Enterprises Recording Positive Revenue Growth | 32 companies | +---------------------------------------------------+---------------------+ ``

This contraction among two-thirds of the country's leading enterprises illustrates a severe margin squeeze. The mechanism driving this downturn involves three interacting factors:

1. Import cost escalation: The exchange rate of 122.75 BDT per USD recorded at end-Dec 2024 has increased the landing costs of imported machinery and active substances.
2. Operating expenditure inflation: Persistent domestic inflation, recorded at an annual average of 10.47% in 2024, has driven up utility charges, transport costs, and administrative expenses.
3. Retail price rigidity: Domestic retail pricing structures restrict the pass-through of imported cost increases onto consumers, compressing operating margins across the top 100 producers.

Working capital financing constraints amplify this compression. With the banking sector non-performing loan ratio reaching 35.73% in late 2025, commercial lenders have curtailed credit lines and tightened collateral standards. Consequently, mid-tier manufacturers face an acute liquidity bottleneck, preventing them from financing long inventory cycles.

Price Competitiveness and Public Health Trade-Offs

Despite input cost increases, domestic finished pharmaceuticals remain inexpensive relative to regional peers. Comparative pricing data compiled by the Bangladesh Association of Pharmaceutical Industries (BAPI) reveals that 30 out of 39 commonly consumed essential medicines are priced lower in Bangladesh than equivalent products in India.

This pricing differential highlights an important policy trade-off. Lower relative prices across 30 out of 39 essential molecules protect low-income households from catastrophic medical expenditures during an inflationary period (with inflation averaging 10.47% in 2024 and 9.7% in Dec 2024). However, holding domestic prices below Indian levels during periods of currency depreciation diminishes the operating cash flows of local producers.

Because domestic producers import raw chemical precursors from international markets, their underlying cost structure reflects international prices, while their revenues remain constrained by domestic price controls. This dynamic explains why 64 of the top 100 manufacturers experienced negative revenue growth in 2025, as price caps prevented firms from adjusting end-product prices to balance foreign exchange movements.

Upstream Vulnerability: The Active Pharmaceutical Ingredient Deficit

The primary structural vulnerability of Bangladesh's pharmaceutical industry lies in its upstream chemical dependencies. While local manufacturers cater to 98% of domestic finished formulations, the sector imports over 85% of its Active Pharmaceutical Ingredients (APIs). This dependency requires an annual expenditure of $1.3 billion to $1.5 billion on imported active substances.

`` +-------------------------------------------------------------------------+ | ACTIVE PHARMACEUTICAL INGREDIENTS | +---------------------------------------------------+---------------------+ | Supply Chain Parameter | Reported Value | +---------------------------------------------------+---------------------+ | National API Import Dependency Ratio | Over 85% | | Annual API Import Expenditure | $1.3 to $1.5 billion| | Molecules Actively Used in Formulations | Approximately 400 | | Molecules Synthesized Domestically | 40 to 41 molecules | +---------------------------------------------------+---------------------+ ``

Domestic synthesis capabilities remain limited. Local synthesis covers only 40 to 41 API molecules out of approximately 400 molecules actively used in local formulations. Consequently, approximately nine-tenths of the necessary chemical entities must be procured from abroad.

This heavy reliance on foreign chemical synthesis creates several structural vulnerabilities:

• Foreign exchange exposure: Procuring imported raw materials at an exchange rate of 122.75 BDT per USD requires an annual outlay of $1.3 billion to $1.5 billion, consuming foreign exchange reserves (which stood at $31.07 billion under IMF BPM6 in Dec 2024).
• Supply chain disruption risks: Relying on overseas suppliers leaves local producers vulnerable to export bans, maritime delays, and factory shutdowns in sourcing countries.
• Value addition ceilings: Without domestic chemical synthesis, local manufacturing remains confined to secondary formulation and packaging, capturing only a fraction of total pharmaceutical value addition.

Export Trajectory and External Market Penetration

External trade has emerged as a resilient growth driver for the pharmaceutical industry, providing foreign exchange earnings that help counter domestic market stagnation. Domestic manufacturers ship finished goods to 166 international markets.

`` +-------------------------------------------------------------------------+ | EXPORT PERFORMANCE TRACK RECORD | +---------------------------------------------------+---------------------+ | Period / Metric | Export Receipts | +---------------------------------------------------+---------------------+ | FY11 Annual Export Receipts | $44.2 million | | FY24 Annual Export Receipts | $205.48 million | | FY25 Annual Export Receipts | $213.16 million | | July 2024 to April 2025 (10-Month FY25 Base) | $177.42 million | | July 2025 to April 2026 (10-Month FY26 Receipts) | $194.63 million | | July-April 10-Month Year-on-Year Growth Rate | 9.7% | | April 2025 Monthly Export Receipts | $11.94 million | | April 2026 Monthly Export Receipts | $23.96 million | | April Year-on-Year Monthly Surge | 100.67% | | Projected Total FY26 Export Revenue (EPB) | Approaching $250 mn | +---------------------------------------------------+---------------------+ ``

Long-term trade records show substantial export growth over the past decade and a half. Export receipts rose from $44.2 million in FY11 to $205.48 million in FY24, expanding further to $213.16 million in FY25.

Recent high-frequency trade data confirms an acceleration in export receipts. Between July 2025 and April 2026, export receipts reached $194.63 million, reflecting a 9.7% year-on-year increase compared to $177.42 million during the corresponding 10-month period of FY25. Export receipts expanded sharply in April 2026, surging 100.67% year-on-year to $23.96 million from $11.94 million in April 2025.

Based on this strong performance through April 2026, the Export Promotion Bureau (EPB) projects total FY26 pharmaceutical export revenue to approach the $250 million threshold. While pharmaceutical exports represent a modest component of the national merchandise export total ($44.5 billion in FY2023-24), expansion across 166 international markets provides crucial foreign exchange liquidity to participating manufacturers.

Institutional Governance and Regulatory Architecture

The institutional governance of the pharmaceutical sector underwent formal restructuring with the enactment of the Drugs and Cosmetics Act 2023. In accordance with this statutory framework, the government established the 22-member National Drug Advisory Council, headed by Health and Family Welfare Minister Sardar Md Sakhawat Husain.

The establishment of this 22-member council centralizes policy coordination across quality standards, industrial pricing, domestic market availability, and regulatory enforcement. Key institutional priorities under this body include:

• Harmonizing pricing frameworks: Designing pricing mechanisms that account for the 122.75 BDT per USD exchange rate and general inflation of 10.47%, while maintaining consumer affordability for the 30 out of 39 essential medicines currently priced below Indian equivalents.
• Addressing industrial concentration: Managing the structural imbalance where 20 companies generate approximately 94% of output, while 238 smaller manufacturers face escalating compliance requirements under the Drugs and Cosmetics Act 2023.
• Quality assurance oversight: Enforcing standardized good manufacturing practices across all 258 registered production units to protect both domestic public health and international supply contracts across 166 export destinations.

Fiscal Adjustments and Tariff Rationalization Levers

To support sector liquidity and encourage domestic manufacturing, the National Board of Revenue (NBR) has advanced several fiscal and tariff proposals. These measures seek to address raw material cost pressures and incentivize higher-value production.

`` +-------------------------------------------------------------------------+ | NBR FISCAL AND TARIFF POLICY PROPOSALS | +---------------------------------------------------+---------------------+ | Targeted Intervention Area | Statutory Mechanism | +---------------------------------------------------+---------------------+ | Concessional Tariff Expansion | Adding 17 raw | | | materials to the | | | concessional list | | Specialized Medical Products | Duty exemptions for | | | anti-cancer inputs | | Backward Integration Support | Duty exemptions on | | | materials for API | | | production plants | | Medical Device Value Added Tax Rationalization | Complete withdrawal | | | of 10% supply-stage | | | VAT on stents and | | | intraocular lenses | +---------------------------------------------------+---------------------+ ``

The NBR proposals focus on four specific fiscal interventions:

1. Adding 17 new basic raw materials to the schedule of concessional import tariffs for medicine manufacturing, directly lowering input costs for domestic formulators.
2. Granting targeted duty exemptions for materials used in anti-cancer medicines, expanding local access to specialized oncology treatments.
3. Providing duty exemptions on construction and process materials for API plants, supporting domestic production to substitute for the $1.3 billion to $1.5 billion spent annually on imported active ingredients.
4. Withdrawing the 10% supply-stage Value Added Tax (VAT) on cardiac stents and intraocular lenses, reducing treatment costs for critical cardiovascular and ophthalmic procedures.

Strategic Reform Priorities for Policy Consideration

Addressing the structural challenges facing the pharmaceutical sector requires sequenced policy implementation across three main areas:

1. Implementing Targeted Tariff Reductions: The Ministry of Finance and the NBR should expedite the proposed additions of 17 new basic raw materials to the concessional tariff list. Granting duty exemptions for inputs used in anti-cancer medicines and API plants will lower landed production costs, mitigating the input cost inflation driven by the 122.75 BDT per USD exchange rate.
2. Scaling Domestic Chemical Synthesis: Expanding domestic API synthesis is necessary to reduce the sector's over 85% import dependency and ease foreign currency outflows, which run at $1.3 billion to $1.5 billion annually. Public policy should incentivize the synthesis of active molecules beyond the current 40 to 41 domestically produced compounds, progressively targeting the broader base of approximately 400 molecules utilized by local formulators.
3. Balancing Price Stability and Industrial Viability: The 22-member National Drug Advisory Council, headed by Health and Family Welfare Minister Sardar Md Sakhawat Husain, must calibrate pricing formulas under the Drugs and Cosmetics Act 2023. This involves balancing affordable access for the 30 out of 39 essential medicines priced below Indian benchmarks against the operational viability of domestic manufacturers, particularly following 2025, when 64 of the top 100 manufacturers experienced negative revenue growth.